Reassuring effect of pravastatin on natural killer cell activity in stable renal transplant patients

Transplantation

Volumn 71, Issue 8, 2001, Pages 1175-1179

  Vaessen, Leonard M B ^a   Van Miert, Paula P M C ^a   Van Gelder, Teun ^a   Uzermans, Jan N M ^a   Weimar, Willem ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CYCLOSPORIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; PRAVASTATINCHOL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; RECIPIENT;

EID: 0035025776     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200104270-00028     Document Type: Article

References (19)

1. Gunnarsson R, Lofinark R, Nondlander R, Nyquist O, Groth CG. Acute myocardial infarction in renal transplant recipients: incidence and prognosis. Eur Heart J 1984; 5(3): 218.
2. van den Dorpel MA, Ghanem H, Rischen-Vos J, et al. Conversion from cydosporin A to azathioprine treatment improves LDL oxidation in kidney transplant recipients. Kidney Int 1997; 51(5): 1608.
3. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997; 278(4): 313.
4. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992; 33(11): 1569.
5. Yoshimura N, Oka T, Okamoto M, Ohmori Y. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992; 53(1): 94.
6. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation [see comments]. N Engl J Med 1995; 333(10): 621.
7. Katznelson S, WangXM, Chia D, et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant 1998; 17(4): 335.
8. Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation: a pilot study. Transplantation 1996; 61(10): 1469.
9. Manilay JO, Sykes M. Natural killer cells and their role in graft rejection. Curr Opin Immunol 1998; 10(5): 532.
10. Chong AS. Receptors that turn on and turn off natural killer cells. J Heart Lung Transplant 1996; 15(7): 675.
11. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187.
12. Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 1996; 34(1): 51.
13. Ghanem H, van den Dorpel MA, Weimar W, et al. Increased low density lipoprotein oxidation in stable kidney transplant recipients. Kidney Int 1996; 49(2): 488.
14. Bouma GJ, van der Meer-Prins PM, van Bree FP, van Rood JJ, Claas FH. Determination of cytotoxic T-lymphocyte precursor frequencies using europium labeling as a nonradioactive alternative to labeling with chromium-51. Hum Immunol 1992; 35(2): 85,
15. Ong CS, Pollock ÇA, Caterson RJ, et al. Hyperlipidemia in renal transplant recipients: natural history and response to treatment. Medicine 1994; 73(4): 215.
16. Cutts JL, Scallen TJ, Watson J, Bankhurst AD. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989; 139(3): 550.
17. McPherson R, Tsoukas C, Baines MG, et al. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol 1993; 13(6): 439.
18. Prince HE, Ettenger RB, Dorey FJ, Fine RN, Fahey JL. Azathioprine suppression of natural killer activity and antibody-dependent cellular cytotoxicity in renal transplant recipients. J Clin Immunol 1984; 4(4): 312.
19. Versluis DJ, Bijma AM, Vaessen LM, Weimar W. Changes in immunological parameters after conversion from cyclosporine A to azathioprine in renal transplant recipients. Int J Immunopharmacol 1989; 11(2): 157.